Patents by Inventor Gerhard Moldenhauer
Gerhard Moldenhauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10730943Abstract: The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.Type: GrantFiled: August 24, 2018Date of Patent: August 4, 2020Assignees: Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH), Deutsches KrebsforschungszentrumInventors: Ulrike Protzer, Felix Bohne, Frank Momburg, Gerhard Moldenhauer
-
Patent number: 10711054Abstract: The present invention relates to a binding molecule comprising at least three binding specificities, wherein (a) the first specificity is for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen; (b) (i) the second and third specificity are for CD3 and CD28, respectively; or (ii) the second and third specificity are selected from specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D; and (c) each binding specificity is provided by one or more binding sites, each binding site being independently provided by (i) a set of six complementarity determining regions (CDRs), wherein said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain; or (ii) a set of three CDRs, wherein said set of three CDRs is comprised in an immunoglobulin domain.Type: GrantFiled: March 16, 2016Date of Patent: July 14, 2020Assignees: Helmholtz Zentrum München—Deutsches Forschungszentrum fur Gesundheit und umwelt (GmbH), DEUTSCHES KREBSFORSCHUNGSZENTRUM, TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Ulrike Protzer, Felix Bohne, Oliver Quitt, Frank Momburg, Gerhard Moldenhauer
-
Patent number: 10513559Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.Type: GrantFiled: November 30, 2015Date of Patent: December 24, 2019Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Heinz Faulstich, Gerhard Moldenhauer
-
Patent number: 10400037Abstract: The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.Type: GrantFiled: September 28, 2015Date of Patent: September 3, 2019Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Peter Altevogt, Sandra Lüttgau, Gerhard Moldenhauer, John Hazin
-
Publication number: 20180362649Abstract: The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.Type: ApplicationFiled: August 24, 2018Publication date: December 20, 2018Inventors: Ulrike Protzer, Felix Bohne, Frank Momburg, Gerhard Moldenhauer
-
Patent number: 10059767Abstract: The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.Type: GrantFiled: September 16, 2014Date of Patent: August 28, 2018Assignees: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GMBH), Deutsches KrebsforschungszentrumInventors: Ulrike Protzer, Felix Bohne, Frank Momburg, Gerhard Moldenhauer
-
Publication number: 20180079798Abstract: The present invention relates to a binding molecule comprising at least three binding specificities, wherein (a) the first specificity is for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen; (b) (i) the second and third specificity are for CD3 and CD28, respectively; or (ii) the second and third specificity are selected from specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D; and (c) each binding specificity is provided by one or more binding sites, each binding site being independently provided by (i) a set of six complementarity determining regions (CDRs), wherein said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain; or (ii) a set of three CDRs, wherein said set of three CDRs is comprised in an immunoglobulin domain.Type: ApplicationFiled: March 16, 2016Publication date: March 22, 2018Inventors: Ulrike PROTZER, Felix BOHNE, Oliver QUITT, Frank MOMBURG, Gerhard MOLDENHAUER
-
Publication number: 20170306015Abstract: The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.Type: ApplicationFiled: September 28, 2015Publication date: October 26, 2017Inventors: Peter ALTEVOGT, Sandra LÜTTGAU, Gerhard MOLDENHAUER, John HAZIN
-
Patent number: 9676855Abstract: The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory.Type: GrantFiled: September 10, 2012Date of Patent: June 13, 2017Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Adelheid Cerwenka, Gerhard Moldenhauer
-
Publication number: 20160200798Abstract: The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.Type: ApplicationFiled: September 16, 2014Publication date: July 14, 2016Inventors: Ulrike Protzer, Felix Bohne, Frank Momburg, Gerhard Moldenhauer
-
Publication number: 20160089450Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.Type: ApplicationFiled: November 30, 2015Publication date: March 31, 2016Inventors: Heinz FAULSTICH, Gerhard MOLDENHAUER, Werner Simon, Jan ANDERL, Christoph MULLER
-
Patent number: 9260521Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: GrantFiled: October 3, 2013Date of Patent: February 16, 2016Assignees: MEDIGENE AG, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFUNG DES OFFENTLICHEN RECHTSInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Patent number: 9233173Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.Type: GrantFiled: April 8, 2010Date of Patent: January 12, 2016Assignees: Deutsches Krebsforschungszentrum, Heinz FaulstichInventors: Heinz Faulstich, Gerhard Moldenhauer, Werner Simon, Jan Anderl, Christoph Müller
-
Publication number: 20140341915Abstract: The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory.Type: ApplicationFiled: September 10, 2012Publication date: November 20, 2014Inventors: Adelheid Cerwenka, Gerhard Moldenhauer
-
Patent number: 8771960Abstract: The invention relates to a method for the production of a protein library, in particular an antibody library, which is highly diverse and for the selection of proteins, in particular antibodies, therefrom.Type: GrantFiled: September 27, 2002Date of Patent: July 8, 2014Assignee: Deutsches KrebsforschungszentrumInventors: Frank Breitling, Gerhard Moldenhauer, Annemarie Poustka, Thorsten Kühlwein, Sandra Lüttgau
-
Publication number: 20140120117Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: ApplicationFiled: October 3, 2013Publication date: May 1, 2014Applicants: MediGene AG, Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen RechtsInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Patent number: 8580258Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: GrantFiled: February 6, 2012Date of Patent: November 12, 2013Assignees: Deutsches krebsforschungszentrum Stiftung des Offentlichen Rechts, Medigene AGInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krueger, Silke Wolterink, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Publication number: 20120258039Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: ApplicationFiled: February 6, 2012Publication date: October 11, 2012Inventors: Daniela Gast, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krüger, Silke Wolterink, Sandra Lüttgau, Ulrich Mõbius, Yi Li
-
Publication number: 20120213805Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of target-binding moieties and toxins that are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moieties (e.g. antibodies) are directed against tumour-associated antigens, such as epithelial cell adhesion molecule (EpCAM). In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer, in particular adenocarcinoma, such as pancreatic cancer, cholangiocarcinoma, breast cancer, and colorectal cancer.Type: ApplicationFiled: April 8, 2010Publication date: August 23, 2012Inventors: Heinz Faulstich, Frank Breitling, Sandra Lüttgau, Gerhard Moldenhauer
-
Publication number: 20120100161Abstract: The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.Type: ApplicationFiled: April 8, 2010Publication date: April 26, 2012Inventors: Heinz Faulstich, Gerhard Moldenhauer, Werner Simon, Jan Anderl, Christoph Müller